Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease

• Published in: Pathogens (Basel) Vol. 12; no. 7; p. 939
• Main Authors: Robledo, Sara M, Pérez-Silanes, Silvia, Fernández-Rubio, Celia, Poveda, Ana, Monzote, Lianet, González, Víctor M, Alonso-Collado, Paloma, Carrión, Javier
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2023; MDPI
• Subjects: Antimicrobial peptides; Antimicrobial resistance; Antiparasitic agents; Cell membranes; cell-penetrating peptides; Chagas' disease; Drug therapy; intracellular pathogen; Leishmania; Leishmaniasis; Parasites; Peptides; Pharmaceutical research; Protozoa; Review; Toxicity; Tropical diseases; Trypanosoma; Trypanosoma cruzi; Vector-borne diseases; Vectors; Zoonoses; Spain; Trypanosoma; cell-penetrating peptides; intracellular pathogen; Leishmania; antimicrobial peptides
• ISSN: 2076-0817; 2076-0817
• DOI: 10.3390/pathogens12070939

In 2020, the WHO established the road map for neglected tropical diseases 2021-2030, which aims to control and eradicate 20 diseases, including leishmaniosis and Chagas disease. In addition, since 2015, the WHO has been developing a Global Action Plan on Antimicrobial Resistance. In this context, the achievement of innovative strategies as an alternative to replace conventional therapies is a first-order socio-sanitary priority, especially regarding endemic zoonoses in poor regions, such as those caused by and spp. infections. In this scenario, it is worth highlighting a group of natural peptide molecules (AMPs and CPPs) that are promising strategies for improving therapeutic efficacy against these neglected zoonoses, as they avoid the development of toxicity and resistance of conventional treatments. This review presents the novelties of these peptide molecules and their ability to cross a whole system of cell membranes as well as stimulate host immune defenses or even serve as vectors of molecules. The efforts of the biotechnological sector will make it possible to overcome the limitations of antimicrobial peptides through encapsulation and functionalization methods to obtain approval for these treatments to be used in clinical programs for the eradication of leishmaniosis and Chagas disease.